Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06619353 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

RCVR (Residual CardioVascular Risk) Prospective Study

Study acronym: RCVR
StatusActive, Not Recruiting
PhaseNot specified
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Trial status: Recruiting to Active, Not Recruitingv2 Show 7 more changesShow less
    • Enrollment target: estimated 1000 to confirmed 500
    • Primary completion date: Jun 17, 2029 to Feb 2029
    • Study completion date: Dec 31, 2029 to Feb 2029
    • Eligibility criteria expanded, about 67 words
    • Secondary endpoints: details revised at 14 of 14 entries
    • Site details revised
    • Study title shortened, about 1 word
  2. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The goal of this observational study is to evaluate whether residual cardiovascular risk assessed at 1 month after percutaneous coronary intervention (PCI) is associated with long-term clinical outcomes in adult patients with coronary artery disease who are free from major adverse clinical events at 1 month after PCI. The main questions it aims to answer are: * Does residual cardiovascular risk at 1 month after PCI predict long-term net adverse clinical events? * Which components of residual cardiovascular risk are associated with subsequent adverse clinical outcomes? Participants will: * Undergo comprehensive laboratory testing at 1 month after PCI and annually thereafter. * Undergo artificial intelligence-based quantitative coronary angiographic analysis using DICOM datasets after PCI. * Be followed annually for up to 3 years after the 1-month assessment to evaluate clinical outcomes.
Trial Details
NCT Number NCT06619353
Lead Sponsor CHA University
Conditions
(from sponsor)		 Coronary Artery Disease
Related terms Coronary Artery Disease
Enrollment 500 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov